Home > Find support > Research Projects > Understanding how the leukaemia gene EVI1 affects children with Fanconi anaemia

Fanconi anaemia (FA) is a rare, inherited blood disorder that leads to bone marrow failure. Children with FA have a greatly increased risk of developing leukaemia. Dr Meyer’s research focuses on a gene called EVI1 which is involved in the development of leukaemia in children both with and without FA. He wants to understand how the FA genetic defect works together with EVI1 in leukaemia development.

Our funding is helping Dr Stefan and his team find out how the EVI1 gene and the FA genetic defect combine to increase a child’s likelihood of developing leukaemia.

Project Details

  • Project Title

    Investigations into the role of EVI1 in Fanconi anaemia associated malignant transformation

  • Lead Researcher

    Stephan Meyer

  • Research Centre

    University of Manchester

  • City & Institution Postcode

    --

  • Start Date

    29 March 2013

  • Duration

    3 years 3 months

  • Grant Amount

    £81,614

scientist doing an experiment
two kids hugging

Patient Story – Lucie

Lucie was diagnosed with a brain tumour when she was only five weeks old.  Her mum Philippa tells their

Read more
Read more
two kids hugging

Media Stories – Brain cancer breakthrough could help doctors give children more effective treatment

An important new discovery about the most common type of malignant childhood brain cancer could transform treatment for

Read more
Read more
two kids hugging

New MRI techniques to improve diagnosis and monitoring of childhood cancer

MRI scans are essential to help us diagnose brain cancers. But current techniques can’t always give us the precise information

Read more
Read more

Overview

Fanconi anaemia (FA) is an inherited disease resulting from a defect in cells which makes them unable to deal with toxins. Children affected by FA experience problems including developmental defects, bone marrow failure and an enormous lifetime risk of leukaemia and other cancers. Around 1 in 10 children with FA develop leukaemia, a risk some 1,000 times higher than those without FA. Research into FA has helped us understand how the body protects its DNA from toxic environmental substances including aldehydes. Aldehydes are produced by natural processes in the body, as well as from dietary sources like alcohol. With FA, the body can’t repair DNA damage caused by exposure to aldehydes and some other chemicals. One of the particular features of leukaemia development in children affected by FA is over-expression of a gene called EVI1; though it can also be activated in leukaemia in children and adults without FA. This project will help us to understand more about the important interaction between FA and EVI1.

What difference will this project make?

This ambitious project will advance our understanding of one of the most aggressive leukaemia genes, EVI1, and how it overrides the body’s normal DNA repair responses and allows leukaemia to develop. The project team is studying EVI1 to understand how it works together with the FA defect in leukaemia development, particularly where environmental toxins are involved. They want to find out how too much EVI1 gives blood cells with an inherited Fanconi defect an advantage, and will study how EVI1 initiates and maintains leukaemia in FA. In addition they’ll find out whether the ways FA and EVI1 interact are affected by exposure to DNA-damaging agents such as aldehydes and radiation. This is really important for the development of new approaches to treating leukaemia. Activation of EVI1 is a bad prognostic marker so understanding its function is vital if we’re to help more children with FA recover from, or ultimately avoid, leukaemia.

About the Research Team

Dr Stefan Meyer is a Consultant Paediatric Oncologist at the Christie Hospital and a Senior Lecturer in Paediatric Oncology at the University of Manchester. His previous work on EVI1 has been published in leading international journals. The Stem Cell and Leukaemia Proteomics Laboratory in Manchester, where this research is being carried out, has a long-standing track record. Together with Dr Stefan’s technical expertise it provides the high-level facilities needed for this complex research.
two kids hugging

Patient Story – Dulcie

Dulcie was diagnosed with stage 4, high-risk neuroblastoma on 9 December 2021, when she was just five years old.

Read more
Read more
two kids hugging

Tracking the long-term health of children, teenagers and young adults treated for cancer in Britain

Children, teenagers and young adults who survive cancer can then face long-term health impacts as a result of their disease

Read more
Read more
two kids hugging

Queen Elizabeth Olympic Park Half Marathon 2024

Make your

Read more
Read more
Newsletter icon
Newsletter icon

Sign up to our e-newsletter today

Sign up to our e-newsletter and receive exclusive stories straight to your inbox. You will also find out about our latest childhood cancer research news along with updates on our fundraising events, charity news and opportunities to support us. Don’t miss out!

By signing up to this newsletter I agree to receive general and financial appeal emails from Children with Cancer UK